RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Neuro, Do you see any significance to the change in terminology that Schering uses in describing their AMPA program? The had been using the 'AMPAkine' term, which is Cortex's patented term, but now have switched to 'AMPA PAM'. This change has been made recently - the last time I looked at Schering's pipeline (5-25-09), they still had it listed as 'AMPAkine'.


Schering previous pipeline entry had been -

>>> AMPAkine : a glutaminergic for Attention Deficit Hyperactivity Disorder (ADHD) and Depression; Compounds from Cortex obtained via the OBS acquisition. <<<


Now their entry reads -

>>> AMPA PAM : a glutaminergic for Attention Deficit Hyperactivity Disorder (ADHD) and Depression; Compounds from Cortex obtained via the OBS acquisition. <<<

The new entry also says -

>>> AMPA PAM*
ADHD, Depression

*formerly AMPAkine <<<